Home > About Xigen : Governance  
 
Pipeline

Governance

At the end of 2009, the company moved from “R” to “D” its two leads compounds with a specific focus on inflammatory diseases. This strategic direction change was reinforced in 2010 with the nominations of seasoned professionals of the pharma industry to the Board of Directors. These have helped the management to transition into clinical development. The Company also decided to externalize the preclinical and clinical development activities through a partnership with SOLID, a Geneva based company specialized in drug development.

Antoine Brézin

MD, PhD, chairs the department of ophthalmology at the Paris Descartes, Paris Centre University Hospital

He has a longstanding interest in the fields of ocular inflammation and cataract surgery. He is the author of the French Society of Ophthalmology book on uveitis and he has published articles in all leading ophthalmology journals.

Soizic Courcier

MD, Soizic Courcier is physician (University Bichat-Beaujon, Paris), graduate in Business Strategy (ESCP) and Public Health, Market Access and Health Security (CNAM)

She joined the pharmaceutical industry for over 30 years. She has held positions of increasing responsibilities in clinical development and medical affairs in different companies, at national & international levels.
Soizic Courcier held the position of Medical and Regulatory Affairs Director from 2007 to October 2015  within GlaxoSmithKline (GSK).
She used to work in different therapeutic areas but mainly in oncology, virology, Immuno-inflammation, respiratory and vaccines
Since November 2015, she is VP Vaccines Medical & Clinical  Europe within GSK Vaccines entity.
She has been involved in many initiatives including in the LEEM where she chaired as President of the Clinical Research Attractiveness group from 2004 until fall 2015.
She is also member of the Executive Committee of ARIIS (Association for Research in Health Industries).

Yannick Pletan

MD, MSc, FFPM

Board-certified pulmonologist and immunologist from the University of Paris with a Master Degree in Clinical Pharmacology and Pharmacokinetics, whose first career part was spent in various university hospitals, as a Clinical Assistant Professor of Respiratory Medicine with a researcher position at INSERM. He joined the pharmaceutical industry in Sanofi as Head of Global Immunology R&D, then moved to Pierre Fabre Research Institute as CMO, Global Head of Development and of R&D Strategy. He then worked for Pfizer as VP-Head of the French Medical & Scientific Division, and for the past 5 years as Country Medical Director of Roche in France as well as a Member of the Global Medical Affairs Council of Hoffmann-Laroche in Basel. He has been the author or co-author of several international guidelines for WHO and later ICH, and of various publications on clinical trial methodology.

Mikhail Sazonov

MBA, Chairman of the Board

Mikhail Sazonov has been involved as a senior financial executive in major pharma and biotech projects as well as in a publicly trading resource business. As a CIO of a family office, he has been running a portfolio of private equity investments. Mikhail holds an MBA with Honors from INSEAD.

  Top